Leading Brazilian Information Security Specialist Kryptus Expands Its Activities in the EMEA Region
12.5.2020 17:55:00 EEST | Business Wire | Press release
Seeking to consolidate its presence and develop new businesses in Europe, Middle East and Africa (EMEA), Brazilian Kryptus, specialized in cryptography and information security, announces the expansion of its international activities with the opening of a new unit of the company in Switzerland. The initiative is focused on offering technical support in the region, as well as develop the market, regional channel partners, and respond to local requirements. The move includes the announcement of Thierry Martin as the new director for EMEA and the head of the Swiss branch.
With a strong cybersecurity background, Martin is an engineer who has led several different technology companies in Europe and Brazil. The executive has also been a member of the Kryptus board in 2016 and 2017.
Currently providing solutions to financial institutions, private companies, and governments around the globe, Kryptus aims through this expansion to reach more customers with its competitive and unique product portfolio. The offerings include kNET, its high-performance HSM with unbreakable encryption, and Commguard, its flexible line of link encryptors.
"Kryptus can deliver world-class, trustworthy, and secure cryptography solutions for critical applications. Our presence in the region allows the optimization of services for customized or custom-developed products, providing a strong value proposition in the EMEA region," says Thierry Martin.
According to Roberto Gallo, founder & CEO of Kryptus, expanding to the EMEA region strengthens the company's position as a strategic provider of cyberdefense for governments and enterprises. "Kryptus can now extend its technology offering to Europe, Middle East, and Africa, based on relevant certifications and high performance," he points out.
With its Headquarter in Campinas, Kryptus was founded in 2003 and counts among its customers companies like BSH (a BOSCH Gmbh subsidiary), Claro Brasil (America Móvil Group), Certisign (exclusive Verisign partner in Brazil), Iron Mountain, iFood and Embraer. Granted the status of Strategic Defense Company (EED) by the Brazilian Defense Council, Kryptus has gained the trust - as a supplier from a neutral country - of several government agencies to protect their sovereignty. Among such customers with the highest security requirements, Kryptus delivered government-grade solutions to the Peruvian Navy, the Colombian Army and the Brazilian Army, Air Force, Navy, Intelligence Agency, Ministry of Foreign Affairs, and Superior Electoral Court, as well as to several other governments.
About Thierry Martin
Thierry Martin was born in Switzerland where he studied Electronics and Computer Science. He has professional experience in various areas of technology, among them Digital TV, Cyber Security, Electronics, and Telecommunications. Along his career he has lived and worked in Switzerland, Spain, the United Kingdom, and Brazil, as well as worked extensively with the United States and Asia. He has held executive positions in companies like Nagra, Kudelski Security, Selectron Systems AG, and Mouvent AG.
About Kryptus
Kryptus is a provider of solutions in Information Security. With 17 years of history and HQ in Campinas (SP), Kryptus SA is an independent Brazilian company that has been growing consistently for the past 10 years, focusing on long term actions, scientific and technological plans, and understanding the mission of its clients in the business lines it develops. Kryptus is a partner of the Kudelski Group. Kryptus is a Brazilian Strategic Defense Company (EED), a status granted by the Brazilian Defense Council.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005624/en/
Contact information
Thierry Martin
+41 79 932 19 23
thierry.martin@kryptus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom